- Precision BioSciences Inc (NASDAQ:DTIL) shared new interim data from the Phase 1/2a study of PBCAR0191 for the patient population with aggressive lymphomas.
- The data demonstrated that PBCAR0191 produced high clinical response rates in CAR T relapsed patients who received a median of five prior lines of therapy.
- Evaluable subjects in the study had 100% ORR, 73% CR rate, and 50% durable response rate greater than six months.
- No Grade 3 or greater cytokine release syndrome (CRS) was observed on the safety front in either dosing cohort.
- One Grade 3 immune effector cell-associated neurotoxicity syndrome was recorded in each cohort that rapidly resolved to Grade 1 within 24 to 48 hours.
- In the New Cohort, two Grade 5 events associated with late-occurring encephalopathy were suspected to be related to fludarabine-associated neurotoxicity. There was no evidence of graft versus host disease in either cohort.
- Precision BioSciences held a cash balance of approximately $121 million as of May 31, sufficient to fund its operating expenses and capital expenditure requirements into mid-2023.
- Price Action: DTIL shares are up 1.91% at $2.13 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Precision BioSciences Highlights Interim Data From Allogeneic CAR T Programs In Blood Cancer Patients
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks